CNR1 and obesity disorder: Obesity-associated hepatic steatosis and dyslipidemia were also significantly reversed in Zucker (fa/fa) rats after 8 weeks of treatment with CB1 specific antagonist, suggesting a direct peripheral effect on carbohydrate and lipid metabolism after blocking CB1 in the liver.